Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (34)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Neu, H. C.
Right arrow Articles by Labthavikul, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Neu, H. C.
Right arrow Articles by Labthavikul, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1986) 17, 441-452
© 1986 The British Society for Antimicrobial Chemotherapy

research-article

The activity of BMY 28142 a new broad spectrum ß-lactamase stable cephalosporin

Harold C. Neu, Nai-Xun Chin, Kethy Jules and Porupen Labthavikul

Departments of Medicine and Pharmacology, College of Physicians and Surgeons, Columbia University New York, N.Y. 10032, U.S.A.

accepted 23 September 1985

Reprint requests to: Department of Medicine, College of Physicians and Surgeons, 630 West 168 Street, New York, New York 10032, U.S.A.

The in-vitro activity of BMY 28142, an iminomethoxy, aminothiazolyl cephalosporin containing a methyl pyrrolidinio C-3 was compared with that of cefotaxime, ceftazidime, aztreonam, imipenem and tobramycin against various bacteria. BMY 28142 was the most active agent tested against the Enterobacteriaceae inhibiting 90% at <1 mg/l. The in-vitro activity of BMY 28142 was equal or superior to cefotaxime against the highly susceptible members of the Enterobacteriaceae and several-fold superior to ceftazidime and aztreonam. BMY 28142 inhibited many Enterobacter cloacae, Citrobacter freundii and Serratia marcescens resistant to cefotaxime, ceftazidime and aztreonam. BMY 28142 was more active than imipenem against Proteus, Providencia and Morganella species. Ceftazidime and imipenem were more active than BMY 28142 against Pseudomonas aeruginosa, but it inhibited piperacillin and tobramycin-resistant isolates. BMY 28142 inhibited ß-lactamase producing Haemophilus influenzae and Neisseria gonorrhoeae. BMY 28142 was more active than ceftazidime against streptococcal and staphylococcal species, but it did not inhibit or kill most methicillin-resistant Staphylococcus aureus. BMY 28142 did not inhibit most Bacteroides species. BMY 28142 was not hydrolyzed by common plasmid and chromosomal ß-lactamases, but it bound poorly to Enterobacter ß-lactamase, was a poor inhibitor of the TEM plasmid ß-lactamase and was a poor inducer of ß-lactamases.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Microbiol. Rev.Home page
G. A. Jacoby
AmpC {beta}-Lactamases
Clin. Microbiol. Rev., January 1, 2009; 22(1): 161 - 182.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
P. D. Lister, W. E. Sanders Jr., and C. C. Sanders
Cefepime-Aztreonam: a Unique Double beta -Lactam Combination for Pseudomonas aeruginosa
Antimicrob. Agents Chemother., July 1, 1998; 42(7): 1610 - 1619.
[Abstract] [Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.